[
  {
    "ts": null,
    "headline": "What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?",
    "summary": "Eli Lilly continues to pursue smart acquisitions for the long term.",
    "url": "https://finnhub.io/api/news?id=993db23775da8aae5fb37f4a814fad17dbf2f9c220658aa2970dc3cb39403d9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771098300,
      "headline": "What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?",
      "id": 139099684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly continues to pursue smart acquisitions for the long term.",
      "url": "https://finnhub.io/api/news?id=993db23775da8aae5fb37f4a814fad17dbf2f9c220658aa2970dc3cb39403d9b"
    }
  },
  {
    "ts": null,
    "headline": "Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25",
    "summary": "Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development priorities for its two lead oncology programs and to reiterate its expected 2025 milestones, including plans to initiate a Phase 3 study in prostate cancer in the first half of the yea",
    "url": "https://finnhub.io/api/news?id=9e48c6832c366196289f56427497354728daa5d31c05ad42b5d0e189116105c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771095859,
      "headline": "Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25",
      "id": 139099685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development priorities for its two lead oncology programs and to reiterate its expected 2025 milestones, including plans to initiate a Phase 3 study in prostate cancer in the first half of the yea",
      "url": "https://finnhub.io/api/news?id=9e48c6832c366196289f56427497354728daa5d31c05ad42b5d0e189116105c9"
    }
  },
  {
    "ts": null,
    "headline": "Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]",
    "url": "https://finnhub.io/api/news?id=caae284984149bb863eea8a6c4ba3619400a37875d71b5efc1b6e39736d8bbb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771050485,
      "headline": "Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings",
      "id": 139093627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]",
      "url": "https://finnhub.io/api/news?id=caae284984149bb863eea8a6c4ba3619400a37875d71b5efc1b6e39736d8bbb4"
    }
  }
]